Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pulse therapy in diffuse connective tissue diseases]

Z Hrncír1

  • 12. interní klinika LF UK, Hradec Králové.

Casopis Lekaru Ceskych
|May 31, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A.

Lupus·2013
Same author

Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study.

Lupus·2010
Same author

[Replacement of aortic valva and ascending aorta in patient with Takayasu's arteritis].

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2010
Same author

[Cognitive dysfunction in patients with systemic lupus erythemathosus with or without antiphospholipid antibodies].

Vnitrni lekarstvi·2007
Same author

Synchronization and information flow in EEGs of epileptic patients.

IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society·2001
Same author

Severe bradycardia after a methylprednisolone "minipulse" treatment.

Archives of internal medicine·2001
Same journal

The personality of professor Otakar Štark in the context of the development of medical genetics in Czechoslovakia in the years 1950-1990.

Casopis lekaru ceskych·2026
Same journal

Václav Náprstek, MD - a forgotten hero.

Casopis lekaru ceskych·2026
Same journal

Professor Otto Piffl, the First Full Professor of Otology and Rhinology at the German University in Prague, passed away 100 years ago.

Casopis lekaru ceskych·2026
Same journal

Ancient sanctuary of Eileithyia, goddess of childbirth, on the island of Paros (Greece).

Casopis lekaru ceskych·2026
Same journal

European Partnership for Personalised Medicine (EP PerMed).

Casopis lekaru ceskych·2026
Same journal

Periodontitis and type 2 diabetes.

Casopis lekaru ceskych·2026
See all related articles

Intravenous pulsed therapies with methylprednisolone, cyclophosphamide, or immunoglobulin effectively manage severe diffuse connective tissue diseases. This approach targets autoimmune mechanisms, offering significant clinical benefits for conditions like rheumatoid arthritis and lupus.

Area of Science:

  • Immunology
  • Rheumatology
  • Genetics

Context:

  • Diffuse connective tissue diseases (systemic autoimmune diseases) present serious clinical and laboratory manifestations.
  • Current therapeutic strategies require effective methods to suppress disease activity.
  • Understanding the immunogenetics of autoimmunity is crucial for developing targeted treatments.

Purpose:

  • To evaluate the efficacy of intravenous pulsed therapies in managing severe manifestations of diffuse connective tissue diseases.
  • To provide a general justification for this therapeutic approach, focusing on immunogenetic aspects.
  • To outline methodical aspects, benefits, and clinical indications for specific autoimmune diseases.

Summary:

  • Intravenous pulsed administration of methylprednisolone, cyclophosphamide, or polyvalent immunoglobulin offers rapid and effective suppression of severe disease activity in diffuse connective tissue diseases.

Related Experiment Videos

  • The therapeutic rationale is grounded in the immunogenetics of pathological autoimmunity, including autogenes and apoptosis.
  • Clinical indications encompass rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis, and primary systemic vasculitis, with potential for future development.

    • Impact:

    • This therapeutic strategy provides rapid symptom control and disease modification in severe autoimmune conditions.
    • It offers a framework for understanding and treating complex autoimmune diseases based on their underlying genetic and immunological mechanisms.
    • Further research into intravenous pulsed therapies may lead to improved treatment protocols and outcomes for patients with diffuse connective tissue diseases.